50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study
Recommended Citation
Stein-Gold L, Tyring SK, Hong H, Pavlovsky L, Pinter A, Reich A, Wu T, Stakias V, Richter S, Papp KA. 50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study. J Am Acad Dermatol 2024; 91(3):AB38.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Background: The phase-4, IMMpulse study (NCT04908475) has demonstrated superior efficacy and safety of risankizumab compared to apremilast in systemic-eligible adult patients with moderate plaque psoriasis (1). Methods: At baseline, 118 patients received subcutaneous risankizumab (150 mg; at labeled dosing), and 234 received oral apremilast (30 mg BID) for 16-weeks (Period-A). This analysis compared efficacy in skin clearance (sPGA0/1, PASI90, PASI75, PASI100) in patients with baseline nail or scalp psoriasis at week-16. Health-related quality of life (PSS0/1, DLQI0/1) and treatment satisfaction (TSQM-9) were also evaluated. Results: At baseline, risankizumab/apremilast groups had comparable demographic and disease characteristics; 93/195 had scalp psoriasis and 62/127 had nail psoriasis. At week-16, risankizumab-treated patients demonstrated significant improvements (P<0.001) from baseline in mean NAPSI (-8.5) and PSSI scores (-14.0) compared to apremilast-treated patients (-5.0 and -6.8 respectively). A higher proportion of patients with scalp psoriasis treated with risankizumab achieved sPGA0/1 (77.4%), PASI90 (57.0%), PASI75 (87.1%), and PASI100 (32.3%) than apremilast (17.9%, 5.1%, 17.4% and 1.5% respectively). A higher proportion of patients with nail psoriasis treated with risankizumab achieved sPGA0/1 (69.4%), PASI90 (48.4%), PASI75 (79.0%), and PASI100 (30.6%) than apremilast (17.3%, 3.9%, 15.0% and 1.6% respectively). Risankizumab-treated patients had favorable PSS0/1, DLQI0/1, and TSQM-9 outcomes compared to apremilast. All results achieved statistical significance (nominal P-values<0.001). Conclusion: Risankizumab demonstrated superior efficacy in skin clearance, quality of life, and treatment satisfaction among patients with baseline scalp or nail psoriasis compared to apremilast at week-16. These results support risankizumab as an effective treatment in systemic-eligible psoriasis patients with high-impact area involvement.
Volume
91
Issue
3
First Page
AB38
